Rocket Lab Reports Material Agreement Changes, Equity Sales

TL;DR

**Rocket Lab just shook up its finances and sold more stock, watch for potential dilution.**

AI Summary

Rocket Lab USA, Inc. (RKLB) filed an 8-K on January 4, 2024, reporting events from December 29, 2023, concerning a material definitive agreement, its termination, and the creation of a direct financial obligation, alongside unregistered sales of equity securities. This indicates significant changes in the company's financial structure and potential dilution for existing shareholders, which could impact the stock's value.

Why It Matters

This filing signals important shifts in Rocket Lab's financial commitments and potential dilution of existing shares, which could affect the stock's price and investor confidence.

Risk Assessment

Risk Level: medium — The filing indicates changes to material agreements and unregistered sales of equity, which can introduce financial uncertainty and potential dilution for shareholders.

Analyst Insight

A smart investor would closely monitor Rocket Lab's upcoming disclosures for specifics on the material agreements and financial obligations, and assess the impact of the unregistered equity sales on share dilution before making any investment decisions.

Key Numbers

• 2023-12-29 — Earliest Event Reported Date (Indicates when the significant events occurred that triggered the 8-K filing.)
• 2024-01-04 — Filing Date (The date the 8-K was officially submitted to the SEC.)

Key Players & Entities

• Rocket Lab USA, Inc. (company) — the registrant filing the 8-K
• December 29, 2023 (date) — date of the earliest event reported
• January 4, 2024 (date) — date the 8-K was filed
• 001-39560 (dollar_amount) — Commission File Number
• RKLB (company) — trading symbol for Common Stock

Forward-Looking Statements

• Rocket Lab's stock (RKLB) may experience short-term volatility due to the reported unregistered sales of equity securities. (RKLB) — medium confidence, target: Q1 2024
• The company's next quarterly earnings call will likely provide more details on the financial obligations and agreements mentioned. (Rocket Lab USA, Inc.) — high confidence, target: Next Earnings Report

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share RKLB The Nasdaq Stock Mar
• $120,000,000 — ent financing in the aggregate of up to $120,000,000 (the “Conditional Commitment&#x2
• $70,000,000 — aws”) to be made as follows: (i) $70,000,000 on the Effective Date (the “Effe
• $40,000,000 — ;Effective Date Draw”); and (ii) $40,000,000 to be drawn on the Effective Date (the
• $30,000,000 — orrowers may make Draws as follows: (x) $30,000,000 to be drawn in not more than three adva
• $10,000,000 — ot more than three advances of at least $10,000,000 each at the Borrowers’ option no
• $20,000,000 — onths after the Effective Date; and (y) $20,000,000 to be drawn at Borrower’s option
• $4.87 — s common stock, at an exercise price of $4.87 per share, payable in cash or on a cash
• $108,648,103 — e released. As of the Effective Date, $108,648,103 of aggregate principal amount, payment-

Filing Documents

• rklb-20231229.htm (8-K) — 44KB
• 0000950170-24-002036.txt ( ) — 160KB
• rklb-20231229_pre.xml (EX-101.PRE) — 10KB
• rklb-20231229.xsd (EX-101.SCH) — 2KB
• rklb-20231229_lab.xml (EX-101.LAB) — 13KB
• rklb-20231229_htm.xml (XML) — 5KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On December 29, 2023 (the “Effective Date”), Rocket Lab USA, Inc. (the “Company”) and certain of its subsidiaries (the “Subsidiaries”, together with the Company, the “Borrowers”), entered into a Master Equipment Financing Agreement (the “Loan Agreement”) with Trinity Capital, Inc., a Maryland corporation (the “Lender”) to provide financing for certain equipment and other property (the “Equipment”). The Loan Agreement provides that the Lender shall provide equipment financing in the aggregate of up to $120,000,000 (the “Conditional Commitment”), with advances (“Draws”) to be made as follows: (i) $70,000,000 on the Effective Date (the “Effective Date Draw”); and (ii) $40,000,000 to be drawn on the Effective Date (the “Blanket Lien Draw”), with each of the Effective Date Draw and Blanket Lien Draw payable over sixty (60) months beginning January 2024, with the final payments due in January 2029. After the Blanket Lien Draw is repaid in full, Borrowers may make Draws as follows: (x) $30,000,000 to be drawn in not more than three advances of at least $10,000,000 each at the Borrowers’ option no later than the date that is 18 months after the Effective Date; and (y) $20,000,000 to be drawn at Borrower’s option between January 1, 2025 and June 30, 2025 (such date, the “Termination Date”), subject to customary conditions. The Borrowers and Lender will enter into one or more equipment financing schedules (individually, a “Schedule” and, collectively, the “Schedules”) from time to time, evidencing a Draw and listing the Equipment to be financed. Each Schedule will constitute a separate financing instrument, and will be effective for the term specified in that Schedule. The monthly payment factors under a Schedule

02 Termination of a Material Definitive Agreement

Item 1.02 Termination of a Material Definitive Agreement. On December 29, 2023, a portion of the proceeds from the Effective Date Draw and the Blanket Lien Draw were used to pay off all obligations owing pursuant to the secured term loan agreement, dated as of June 10, 2021, between the Company and Hercules Capital, Inc. (the “Hercules Capital secured term loan”), which was scheduled to mature on June 1, 2024, and following the payment of the outstanding obligations under the Hercules Capital secured term loan, the Hercules Capital secured term loan, together with all documents and agreements executed in connection therewith, were terminated and all liens associated therewith were released. As of the Effective Date, $108,648,103 of aggregate principal amount, payment-in-kind interest, end of term charges and accrued interest was outstanding under the Hercules Capital secured term loan and repaid with a portion of the proceeds from the Effective Date Draw and Blanket Lien Draw. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

02 Unregistered Sales of Equity Securities

Item 3.02 Unregistered Sales of Equity Securities. The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The issuance of the Warrant was exempt from the requirements of the Securities Act of 1933, as amended, pursuant to an exemption provided by Section 4(a)(2) thereof and Rule 506(b) of Regulation D thereunder as transactions by an issuer not involving a public offering.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROCKET LAB USA, INC. Date: January 4, 2024 By: /s/ Adam Spice Adam Spice Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR